Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 941 | 982 | 1024 | 1447 | 1557 | 2981 |
Fund Return | -5.95% | -1.79% | 2.41% | 13.11% | 9.26% | 11.54% |
Place in category | 1100 | 5246 | 628 | 322 | 1416 | 310 |
% in Category | 17 | 81 | 10 | 7 | 43 | 18 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Nykredit Invest Taktisk Allokering | 9.94B | 2.99 | 1.44 | 5.60 | ||
Nykredit Invest Globale Fokusak Akk | 6.57B | 12.19 | 10.11 | 11.91 | ||
Nykredit Invest Baredygtige Aktier | 4.48B | 8.06 | 10.00 | 11.50 | ||
Nykredit Invest Globale Aktier Basi | 4.25B | 8.03 | 13.08 | 11.63 | ||
Nykredit Invest Globale Fokusaktier | 3.45B | 9.24 | 10.79 | 12.21 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Danica Balance 100 Offensiv | 35.24B | 9.60 | 6.67 | 8.72 | ||
Nordea Invest Portefolje Aktier | 28.29B | 9.20 | 8.86 | 10.22 | ||
Danske Invest Engros Flexinv Aktier | 14.64B | 11.50 | 8.63 | 9.39 | ||
Nordea Invest Global Stars | 3.51B | 5.94 | 7.52 | 11.04 | ||
Formuepleje LimiTTellus | 10.94B | 8.49 | 6.09 | 9.83 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Microsoft | US5949181045 | 5.15 | 406.66 | +2.22% | |
Alphabet A | US02079K3059 | 3.93 | 167.21 | +0.35% | |
Apple | US0378331005 | 3.62 | 183.36 | +5.97% | |
AbbVie | US00287Y1091 | 2.34 | 163.79 | +1.85% | |
Bristol-Myers Squibb | US1101221083 | 2.18 | 43.98 | +0.65% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Neutral |
Technical Indicators | Strong Sell | Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review